Low Dose Atropine for Symptomatic Vitreous Floaters

Status unconfirmed · Phase 2

Conditions studied: Vitreous Floaters

In brief

The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.

Key facts

Study ID

NCT06174935

Run by

Jeanette Du

People needed

200

Starts

2024-01-01

Expected to finish

2024-06-01

Last updated by the study team

2023-12-18

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients within Prism Vision Group with ICD diagnosis of acute posterior vitreous detachment and none of the ocular comorbidities listed as exclusion criteria will be screened as potential study participants.

You may not qualify if…

• Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal pathology, or history of pars plana vitrectomy will be excluded.

Where it is running

• Retina Group of Washington — Reston, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.